ERBB2 and breast cancer: In breast cancer, HER2 amplification status is a pivotal biomarker in predicting response to chemotherapy [8], and a humanized anti-HER2 monoclonal antibody (trastuzumab) improved the survival of HER2-positive breast cancer patients [9].